Drug-Induced Myopathy / Rhabdomyolysis – Decision Support Tool

Drug-Induced Myopathy/Rhabdomyolysis – Interactive Decision Tool

Drug-Induced Myopathy / Rhabdomyolysis – Decision Support

Screen • Timing • Labs • Severity • Likelihood • Causality • Differentials • Management • PV Reporting • Summary

1) Patient & Exposure

Risk factors

2) Symptoms & Signs

3) Labs

4) Timing – TTO

Fill dates above to auto-calculate. Interpretation depends on drug class (see “Risk window fit” on the right).

5) Pattern & Severity (auto)

Pattern

–

Severity tier

–
Based on CK, AKI, electrolytes.

Risk window fit

–
Action: Stop suspect drug; check CK, electrolytes, renal function; begin fluids if rhabdomyolysis suspected.

6) Rhabdomyolysis Likelihood – Quick Score (0–10)

ADR likelihood: –
Add inputs to compute.
0/10

7) Causality Assessment

WHO-UMC helper

WHO-UMC category: —
This is a rule-of-thumb mapping for bedside use.
Advanced: Naranjo mini-calculator
Naranjo score: 0 Category: —
Definite ≥9 • Probable 5–8 • Possible 1–4 • Doubtful ≤0

8) Alternatives considered

9) Management – Smart Suggestions

    10) Case Summary

    For decision support; follow local protocols/consult specialists for emergencies.

    11) Pharmacovigilance (Regulatory Reporting)

    Seriousness (select all that apply)

    Seriousness result

    —
    Select criteria above. Auto-suggests based on severity.

    Expedited rule

    —
    Based on role, region, expectedness, trial.

    Report due

    —
    Uses awareness date + timeline.
    Routing/Channel: —
    Minimum case info (E2B(R3) “four min”): identifiable patient, identifiable reporter, suspect product, adverse event. Add dates, dose, outcome, labs, dechallenge, relevant history.
    What gets expedited where?
    • USA (FDA), MAH: 15 days for serious & unexpected ICSRs (postmarketing). Others go to periodic reports (PADER/PSUR) per requirements.
    • EU/EEA (EMA), MAH: 15 days for all serious ICSRs; 90 days for non-serious → EudraVigilance.
    • UK (MHRA), MAH: mirrors EU: serious 15 days; non-serious 90 days → MHRA Gateway/ICH E2B(R3).
    • Canada (Health Canada), MAH: 15 days for serious ADRs (expectedness not required); non-serious to periodic/aggregate.
    • Australia (TGA), sponsor: Serious 15 days; non-serious 90 days for medicines.
    • Clinical trials (SUSAR), sponsor: Fatal/life-threatening 7 days (+8-day follow-up); other SUSARs 15 days to regulators/ethics (per ICH E2A/EU CTR/local law).
    • HCP/Patient: Report as soon as possible via national portals (e.g., FDA MedWatch, MHRA Yellow Card).